1/147
Looks like no tags are added yet.
agents of STIs - bacteria (3)
Chlamydia trachomatis -> Chlamydia
Neisseria gonorrhoeae -> Gonorrhoea
Treponema pallidum -> Gonorrhoea
agents of STIs - viral (4)
Herpes simplex virus (HSV) -> genital ulcers
Human immunodeficiency virus (HIV) -> HIV and AIDS
Human papillomavirus (HPV) -> genital warts
Hepatitis B virus -> Hep B
agents of STIs - protozoa (1)
Trichomonas vaginalis -> vaginitis
agents of STIs - arthropods (2)
Phthirus pubis -> public lice
Sacroptes scabiei -> scabies
features of bacteria commonly causing STIs - list (7)
Highly infectious
No animal reservoir
Don't survive well outside host
Damage predominantly caused by immune response
Effectively treated by antibiotics -> patients and contacts
Prevented by condoms
Can be asymptomatic
strain - def
population of organisms that descend from single organism or pure culture
serovar (serotype) - def
variant strain of microbe that has distinct antigenic properties
genotype - def
specific set of alleles or genes carried in genome of an organism
infections caused by chlamydia - list (3)
genital infections
ocular infections
respiratory infections
infections and conditions caused by chlamydia trachomatis serovars D-K (4)
Conjunctivitis
Uro-genital tract infections
Reactive arthritis
Pneumonitis
chlamydia as an STI - features (4)
Most common bacterial STI globally
Typical symptom = discharge -> urethritis and cervicitis
Most infections = asymptomatic -> still infectious
Persistent infections common
chlamydia trachomatis - common sites of infection (5)
Cervix
Urethra
Pharynx
Rectum
Eye -> where columnar epithelial cells present
chlamydia trachomatis - infection summary (3)
Can ascend upper genital tract to cause infection, damage and infertility
Eg. endometritis, salpingitis, pelvic inflammatory disease, epididymitis, proctitis
Infection in newborn contraction during birth process -> conjunctivitis
chlamydia trachomatis - morphology (4)
Gram negative -> outer membrane LPS is truncated and not very endotoxic
Abnormal peptidoglycan
Small and non-motile
Obligate intracellular bacteria -> need host cell mitochondria for energy
chlamydia trachomatis - lifecycle stages (2)
Unique replication cycle (2-3 days) with distinct developmental stages
EB = infectious extracellular particles
RB = intracellular and in replicative phase -> do not survive outside cells
chlamydia trachomatis - lifecycle steps (5)
Elementary body (EB) binds columnar epithelial cells by adhesins to enter via receptor mediated endocytosis
No fusion of EB-containing endosome with lysosome -> multiple endosomes fuse to form an inclusion
EB transforms into metabolically active reticulate body (RB) -> replicates inside inclusions
Prolonged RB phase -> persistence
RB converted back to EB
Release of EB from epithelial cell
chlamydia trachomatis - tissue damage summary
Damage caused predominantly by host immune response -> chronic inflammation
chlamydia trachomatis - recurrence of infection
Infections can recur -> more damage = no lasting immunity
Long term sequelae = ascending inflammatory damage -> non-invasive infection
Eg. pelvic inflammatory disease, infertility, ectopic pregnancy
chlamydia trachomatis - tissue damage steps (4)
Infected epithelial cells produce chemokines and other immune mediators → influx of immune cells inc. neutrophils
Innate and adaptive immune activation and cell death
Continued immune activation → chronic inflammation -> cell damage and scar tissue formation
Activated CD4+ and CD8+ T cells and macrophages produce IFN-gamma → prolonged RB phase
chlamydia diagnosis - methods list and summary (2)
specimens → (self-administered) cervical or urethral swabs or first-pass urine
tests → PCR on first pass urine or discharge samples or antigen detect via EIA RAT on self-collected vaginal swabs
chlamydia diagnosis - reasoning for first pass urine
First-pass urine = more concentrated epithelial cells as opposed to mid-stream sample for UTIs
chlamydia - treatment (4)
Antimicrobials target RBs -> require good penetration of tissues and cells
Preferred treatment = single dose of long-acting macrolide or 1 week dose of tetracycline
Macrolide antibiotics and tetracyclines = good tissue/ cell penetration a
Long acting or multiple doses required because life cycle is asynchronous and 2-3 days
Neisseria gonorrhoea - morphology (5)
Gram negative diplococcus -> often intracellular
Extremely fastidious
Grows best in CO2 enriched atmosphere
Similar clinical presentations to chlamydia
Motile
Neisseria gonorrhoea - implications of being motile
Females: bacteria may ascend genital tract -> PID
May also cause disseminated disease but rare
Neisseria gonorrhoea - symptoms (4)
When symptomatic, presents as urethritis a few days after contact -> other sites may be asymptomatic
Females have more asymptomatic infection than males
Newborns may contract conjunctivitis
Symptoms of pus and pain generally more severe than in chlamydial infection
neisseria gonorrhoea - life cycle steps (4)
Targets mucosal columnar epithelial cells -> attaches via adhesins
Eg. pili, outer membrane proteins, lipo-oligosaccharide (form of LPS)
Typically replicates at cell surface and spreads in mucosal secretions → pili have twitching motility
May invade some cells -> translocation to sub-epithelial tissues to cause inflammation and dissemination
Invasion to cause systemic disease rare but possible
Antigenic variation in pili and gonococcal surface proteins allows avoidance of antibody responses and prolongs infections
neisseria gonorrhoea - method to cause tissue damage and evade immune response (4)
Inflammatory response stimulated by LPS and peptidoglycan -> interaction with PRR and TLR
Can avoid killing by neutrophils and complement → invasive strains have altered LPS which lack certain outer membrane proteins
Production of IgA protease -> cleaves IgA so it can't opsonize bacteria and mark for phagocytosis
TNR production -> loss of ciliated epithelial cells
neisseria gonorrhoea - immunity
Re-infections common so no immunity from prior infection
neisseria gonorrhoea - importance of diagnosis and treatment
Early diagnosis and treatment needed to reduce possible sequalae of PID and infertility
neisseria gonorrhoea diagnosis - methods list summarised (3)
Specimens:
collect discharge/ swab from urethra, cervix or other and gram stain and culture
PCR -> collect urine, self-administered vaginal swab
antigen detection via EIA RAT on self-collected vaginal swabs now available
microscopy → gram stain shows intracellular and extracellular Gram-negative diplococci and polymorphonuclear neutrophils
culture on GC biplate → has lysed blood and other components to control growth of normal microbiota, non-antibiotic side used as control and to identify antib
neisseria gonorrhoea - implications if not treated properly
Rapid antibiotic resistance and persistence if treatment incorrect -> efficient acquisition of genetic material from other sources
Horizontal gene transfer and naturally competent
neisseria gonorrhoea - treatment process (3)
Use antibiotic guidelines for current recommendations for empirical treatment
Culture = essential to determine antibiotic susceptibility
Currently: injectable beta-lactamase resistant cephalosporin and azithromycin → high rate of co-infection with chlamydia so beneficial to treat all patients with gonorrhoea with azithromycin as well
treponema pallidum - morphology (5)
Slender, spiral rod
Need special techniques to visualise -> eg. dark field microscopy
Motile -> periplasmic contractile flagella for corkscrew like movement
Very labile -> easily inactivated
Difficult to culture -> requires mammalian cell culture
treponema pallidum - infection summary (3)
Infection may be asymptomatic or symptomatic
Infection = invasive and spreads to region beyond initial infection
Can spread via placenta to foetus -> congenital infection
treponema pallidum - stages of infection and transmission list (4)
Infection -> ~3 week incubation period
Primary syphilis
Secondary syphilis
Tertiary syphilis
Less common since testing/ treatment available
Targets eyes, ears, heart, brain -> eg. neurosyphilis
Patients may present with gummas -> non malignant tumours that degrade bone
treponema pallidum - primary syphilis symptoms (2)
Chancre (ulcer on point of infection site) or asymptomatic -> lesions very infections
Asymptomatic/ latent for 2-24 weeks
treponema pallidum - secondary syphilis symptoms (4)
Rash typically on hands and feet → lesions are infectious
Warty genital lesions
Lymphadenopathy
Asymptomatic/ latent for 3-30 years
treponema pallidum - tertiary syphilis symptoms (3)
Less common since testing/ treatment available
Targets eyes, ears, heart, brain -> eg. neurosyphilis
Patients may present with gummas -> non malignant tumours that degrade bone
treponema pallidum diagnosis - methods list (2)
Swab from primary or mucosal secondary lesion → dark-ground microscopy or PCR from exudate
Blood specimen → serological test for specific antibodies to treponemal antigens or for cross reactive antibodies to cardiolipin
treponema pallidum diagnosis - downside of serological testing for specific antibodies to treponemal antigens
Usually remain positive for life -> can only tell you if you have active syphilis or previously infected
treponema pallidum diagnosis - benefit of serological testing for cross reactive antibodies to cardiolipin
Correlates with disease activity -> identify if syphilis is active
Used to confirm active infection and to monitor response to treatment
treponema pallidum - treatment
Sensitive to penicillin -> use long acting penicillin
No reported resistance to penicillin -> some to azithromycin
treponema pallidum - importance of treatment (2)
prevents:
progression to tertiary syphilis that can develop from latent infection
congenital syphilis and its complications -> screen for antibodies during all pregnancies
herpesvirus - morphology (4)
Large and icosahedral
Enveloped -> lipid membrane is fragile
Double stranded linear DNA
Encode a large array of proteins -> enzymes, structural proteins, immune evasion
latency of herpesvirus
All Herpesviridae family members can remain latent in the host → eg. chickenpox, glandular fever, roseola infantum, Kaposi's sarcoma
Very common -> can almost regard HSV as normal flora
methods of herpes virus transmission - list (4)
Saliva
Vesicle fluid
Sexual contact
Birth canal
Infection usually requires direct contact -> enveloped viruses are labile
herpesvirus - serotypes (2)
HSV-1 and HSV-2
Can be distinguished by serological tests to detect antigens or PCR to detect genes
Both cause localised infections (eg. cold sores, genital herpes) and disseminated infections (eg. encephalitis, meningoencephalitis)
target cells of herpesvirus and method of entry
epithelial cells, fibroblasts and macrophages -> needs to infect skin
Gains entry via damaged skin or defective keratin layer
Mucous membranes have multiple target cells
herpesvirus - replication in epithelial cell steps (8)
Glycoproteins on envelope (gpB and gpC) bind cell surface receptors inc. heparan and sulphate -> not sufficient for entry
Viral entry by fusion or endocytosis
Binding triggers endocytosis of virus
Binding triggers fusion of envelope with cell membrane
Capsid release into cytoplasm
Ds DNA enters nucleus and forms an episome
Early mRNAs express proteins including DNA polymerase and thymidine kinase
Viral linear dsDNA replicated
Later mRNAs express structural proteins that package new genomes
Virion particle maturation with envelope glycoprotein and release
herpesvirus - progression to disease
Production of large amounts of infectious virus leads to cell-cell spread and cell death -> loss of epithelial cells leads to formation of vesicles/ ulcers
Can spread from peripheral sites to CNS -> systemic damage
herpesvirus - disease symptoms
Infection may be asymptomatic
Transmission to non-immune contacts can occur during symptomatic or asymptomatic replication
HSV-1 - transmission summary
typically infects above the waist and spread by saliva
HSV-2 - transmission summary
typically spread by genital secretions
HSV-1 - signs and disease caused (6)
Cold sores
Gingivostomatitis
Herpetic whitlow
Keratoconjunctivitis
Encephalitis
Meningoencephalitis
HSV-1 - signs and disease caused
Predominantly causes genital herpes and neonatal herpes
herpesvirus - serotypes and cross-protection
Antibodies against HSV-1 partially protect against HSV-2
establishment of herpesvirus latency at primary infection - steps (3)
HSV infection of epithelial cells results in rapid virus multiplication, apoptosis and spread
Vesicles containing HSV form and infect sensory neurons
Axonal transport to dorsal root ganglion results in latent infection
Virus genome maintained as circular DNA episome in ganglia nucleus
Few viral genes are expressed
Latency activated transcript RNAs (LATs) produced but no protein product
reactivation of herpesvirus at primary infection - steps (3)
Certain stimuli and immunosuppression induces reactivation of HSV from episomal state
Some products of early genes seen in human trigeminal cell
Virus is transported down sensory nerve
Reinfection at mucocutaneous site results in fresh outbreak of vesicles or asymptomatic shedding
herpesvirus - maintenance of latency
latency stimulates immune system which tries to suppress reactivation
Large numbers of memory T cells, chemokines and cytokines = associated with HSV-1 infected ganglia
site of HSV latency for HSV-1 and HSV-2
HSV can spread from epithelial cells to dorsal root ganglia -> trigeminal ganglia for HSV-1 and sacral ganglia for HSV-2
innate defences induced by HSV (3)
PAMP-PRR interaction stimulate macrophages and dendritic cells to produce cytokines -> esp. IFN-alpha
Infected epithelial cells produce type 1 interferons (IFN-beta)
Type 1 interferons protect uninfected cells from virus infection and induce influx and activation of NK cells -> recognise and bind to HSV infected cells and lyse them
adaptive immune responses to HSV infection - cell-mediated (4)
CD4+ T cells important to provide help for activation of CD8+ T cells
Cytotoxic CD8+ T cells important in controlling HSV replication in skin/ mucosa and ganglia -> production of ICP47 by HSV infected cells inhibits MHC-I presentation and expression
HSV specific CD8+ T cells found clustered around ganglia but no damage is observed -> virus infection sustained but controlled
In genital lesions: migration of CD8+ T cells correlates with viral clearance
adaptive immune responses to HSV infection - humoral (3)
Maternal antibodies protect against neonatal infection during recurrences of maternal genital disease -> antibodies appear to have limited efficacy in protecting against all forms of HSV infection
Antibodies induced by experimental vaccines have not been associated with protection
Antibody deficient patients have few problems with recurrences compared to individuals with the antibody
immune defence against HSV infection in epithelial cells vs neurons
epithelial cells: replication stimulates complement activation, NK cell activation, T cell activation (although delayed by ICP47 production) and antibody production → lyse virus and or virus infected cells to eventuallt resolve infection
neurons: virus persists
cause of HSV persisting in neurons - list (3)
Limited production of viral proteins in episomal state
Low levels of neuron MHC class I expression
ICP47 inhibition of peptide transport to MHC-I
diagnosis of HSV infection - methods list (3)
Grow virus -> slow and expensive
Look for antigens or nucleic acids
Look for antibodies
interpretation of HSV results - importance
Interpretation of results indicates whether a new or a recurrent episode of a latent infection
Important if genital infection occurs late in pregnancy -> baby may be at risk of contracting the virus during delivery
interpretation of HSV results - features (3)
Acute phase of infection: rapid increase in presence of HSV antigen and nucleic acid that are readily detected
Initial increase in IgM production, followed by production of IgG
Concentrations of IgM or IgG indicate whether it’s a new or recurrent episode
Change of transmission is higher during primary infection -> higher viral load
treating HSV infection - drug summary (3)
Acyclovir = guanosine (nucleoside) analogue used to treat HSV -> inhibits viral DNA replication in epithelial cells (not neurons)
Nucleoside = no phosphate groups → nucleoside analogues = lack 3' hydroxyl group required to form DNA polymer
Nucleotides = nucleosides that are phosphorylated at position 5 -> substrates for DNA polymerisation
treating HSV infection - benefit of acyclovir
Acyclovir only functions in herpesvirus infected host cells -> requires herpesvirus thymidine kinase
treating HSV infection - acyclovir mechanism (3)
Acyclovir is mono-phosphorylated by herpes virus thymidine kinase -> host cell has no enzyme that can mono-phosphate acyclovir
Further phosphorylated by host cell kinases
Tri-phosphorylated acyclovir is in its active form -> can bind to DNA polymerase and terminate DNA polymerisation
No 3' hydroxyl for phosphodiester bond with next nucleotide -> premature termination
HSV control and management strategies - list (4)
No effective vaccines yet but will have to induce T and B cell responses
Antiviral therapies = effective in preventing/ reducing blisters -> cannot remove latent infection in neurons
Physical barriers can reduce spread → eg. condoms and gloves
Limited by virus being able to be shed by asymptomatic and symptomatic individuals
HSV and HIV correlation
HSV-2 genital disease = associated with increased transmission of HIV
global impact of HIV and AIDS (2)
Predominantly infects people in southern and sub-Saharan Africa
1/3 of deaths occur in Sub-Saharan Africa -> decreasing economic growth and increasing poverty
reasons behind difficulty in defeating HIV (5)
Adds its viral genome into host DNA causing permanent infection -> even when infected cells produce no new virions
Sustains highest mutation rate in biology
Transmitted by intimate human contact
Infects stigmatized populations of people
Infects crucial cells of immune system causes acquired immune deficiency syndrome (AIDS)
HIV modes of transmission - general list (3)
parenteral
sexual
mother to child
HIV modes of transmission - parenteral (3)
Blood transfusion
Needle-sharing during injection drug use
Percutaneous
HIV modes of transmission - sexual (5)
Receptive anal intercourse
Receptive pen-vaginal intercourse
Insertive and intercourse
Insertive peno-vaginal intercourse
Unprotected sex with HIV infected individuals on ART
HIV modes of transmission - mother to child (2)
Without prevention measures
With prevention measures including ARV prophylaxis
structure of HIV (6)
Enveloped virus -> needs moist transmission fluid to survive in environment and transmit successfully
Envelope glycoprotein = made of 2 subunit → GP 120 and GP 41
Matrix layer underneath envelope -> P17 protein
Cone shaped core -> composed of icosahedral capsid
Duplicate copies of full length viral genome coded by nuclear capsid protein
Series of enzymes coded off pol gene -> reverse transcriptase, integrase, protease
structural proteins of HIV - gap and pol genes
expressed as one polyprotein before autocleavage
structural proteins of HIV - summary (4)
very high rate of variability -> esp. for gag and envelope proteins
Envelope glycoproteins = expressed from spliced RNA -> only protein available to immune system
Gag -> structural proteins of capsid, matrix, core and nucleocapsid
Pol -> reverse transcriptase, integrase and protease
Phases of HIV infection - summary (3)
primary infection → occurs within first weeks and months
clinical latency
opportunistic diseases
phases of HIV infection - primary infection features
occurs within first weeks and months
Rapid plummet in body and blood CD4+ T cells and rapid rise in plasma viremia
consequences of primary HIV infection (2)
HIV infects and kills >60% of gut associated lymphatic T cells in mucosa within days -> both active and resting memory T cells compromised
Loss of cytokines produced by immune cells leads to leakage of microbial produces across tight junctions (microbial translocation)
phases of HIV infection - clinical latency features (2)
Balance between levels of virus produced and immune response against virus until virus overcomes immune response
Initial immune response to HIV is vigorous and initially contains HIV replication -> establishes virological set point
phases of HIV infection - escape of HIV from immune system causes (4)
Extremely high rival mutation rate
Deletion of HIV-specific CD4 T cell clones
Failure of HIV specific Ab and CTL responses
Other mechanisms
phases of HIV infection - clinical latency monitoring
Equilibrium between viral replicative capacity and host anti-HIV defence can be measured using RT-PCR (reverse transcriptase PCR)
undetectable viral load considered to be <50 copies/ ml (>50 is considered to b AIDS)
effects of HIV on innate immune cells (3)
Neutrophils → reduced killing of bacteria
Macrophages → decrease phagocytosis and chemotaxis + decreased killing
Natural killer cells → decrease virus/ tumour cell killing
effects of HIV on adaptive immune cells (2)
B cells:
General increase in antibodies -> typically autoantibodies as no T cell activation
Poor response to vaccines
Reduced killing encapsulated bacteria
T cells:
Decreased T helper cells for B cell and APC activation
Decrease cytotoxic T cell to lyse other virally infected cells
HIV replication and immune system activation
Immune system activation can drive HIV replication
T cells = most productive at shedding new infectious virus particles
implications of HIV being active at all times even when patient feels well
If patient has been feeling sick for only a short time, they are likely to have been infected for years
HIV antivirals - targets listed (7)
Antiviral drugs predominantly target viral enzymes and structural protein functions at many steps of replication
Attachment -> eg. CCR5 inhibitors
Fusion -> block activity of envelope glycoproteins in drawing the two membranes together
Uncoating -> eg. capsid inhibitors that prevent uncoating and assembly steps
Reverse transcription -> eg. NRTIs and NNRTIs
Integration of viral genome into host DNA -> eg. integrase inhibitor
Assembly and budding -> eg. capsid inhibitors
Maturation -> eg. protease inhibitors
HIV - HAART meaning
highly active anti-retroviral therapy
combination therapy with synergistic potency
purpose of HAART for HIV
Durable antiviral response
Minimises development of drug resistance -> combination of drugs reduces chance of developing drug resistance by overcoming high mutation rate
clinical benefit of HIV antiretroviral therapy to individual (6)
Decreased plasma HIV viral load
Decreased inflammation and immune activation
Decreased CD4+ reservoir size
Decreased mortality
Increased CD4+ cell count and immune health -> gut and lymph node integrity
Increased longevity
benefit of HIV antiretroviral therapy on transmission reduction (2)
Decreased HIV transmission to sexual partners
Decreased transmission to infecting partners and neonates
econological benefit of HIV antiretroviral therapy (2)
Decreased community HIV viral load
Decrease in HIV incidence in communities
HAART on HIV and AIDS
Prior to HAART -> infection with HIV associated with very low probability of survival
Late HAART era patients still have ~10 year shorter life expectancy than HIV-positive controls
Adhering to HAART regiment → shift to non-AIDS related causes of morbidity and mortality
Eg. heart disease, non-AIDS cancers, liver disease
UNAIDS - goal
end AIDS epidemic
90% diagnosed
90% on treatment
90% virally suppressed
UNAIDS targets has reduced deaths